Shopping Cart
Remove All
Your shopping cart is currently empty
Erlizumab is a monoclonal antibody against Integrin b2/ITGB2/CD18 subunit of Mac-1 receptor. By blocking the interaction between CD18 on the surface of leukocytes and adhesion molecules of vascular endothelial cells, Erlizumab can effectively inhibit the recruitment and infiltration of inflammatory cells, thus alleviating the tissue damage in myocardial ischemia-reperfusion injury.

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | Inquiry | Inquiry | |
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Erlizumab is a monoclonal antibody against Integrin b2/ITGB2/CD18 subunit of Mac-1 receptor. By blocking the interaction between CD18 on the surface of leukocytes and adhesion molecules of vascular endothelial cells, Erlizumab can effectively inhibit the recruitment and infiltration of inflammatory cells, thus alleviating the tissue damage in myocardial ischemia-reperfusion injury. |
| Synonyms | rhuMAb |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | Integrin b2/ITGB2/CD18 |
| Cas No. | 211323-03-4 |
| Isotype | IgG1 |
| Storage | Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.